Adverum Biotechnologies to Present at Upcoming Investor Conferences
February 21 2017 - 8:30AM
Adverum Biotechnologies, Inc. (Nasdaq:ADVM) a gene therapy company
committed to discovering and developing novel medicines for
patients suffering from diseases with few or burdensome treatment
options, announced today that Amber Salzman, Ph.D., president and
chief executive officer of Adverum, will present at two upcoming
investor conferences:
- Cowen and Company 37th Annual Health Care ConferenceDate:
Monday, March 6, 2017 Time: 2:40pm ETLocation: Boston, MA
- 29th Annual ROTH ConferenceDate: Monday, March 13, 2017Time:
7:30am PTLocation: Laguna Niguel, CA
The audio portions of the corporate presentations will be
accessible live through the investors’ section of the Company’s
website at www.adverum.com. A replay will be available for 14 days
following the presentations.
About Adverum Biotechnologies,
Inc.Adverum is a gene therapy company committed to
discovering and developing novel medicines that can offer
life-changing benefits to patients living with rare diseases or
diseases of the eye who currently have limited or burdensome
treatment options. Adverum has a robust pipeline that includes
product candidates to treat wet age-related macular degeneration
(wAMD), alpha-1 antitrypsin (A1AT) deficiency, and hereditary
angioedema (HAE). Leveraging a next-generation
adeno-associated virus (AAV)-based directed evolution platform, the
Company generates product candidates designed to provide durable
efficacy by inducing sustained expression of a therapeutic protein.
Adverum has collaboration agreements with Regeneron Pharmaceuticals
to research, develop, and commercialize gene therapy products for
ophthalmic diseases and Editas Medicine to explore the delivery of
genome editing medicines for the treatment of inherited retinal
diseases. Adverum has clinical development expertise and core
capabilities in vector optimization, process development,
manufacturing, and assay development. For more information please
visit www.adverum.com.
Contact for Adverum:
Leone Patterson
Chief Financial Officer
Adverum Biotechnologies, Inc.
650-665-7222
lpatterson@adverum.com
Jill Steier
Senior Vice President
The Trout Group LLC
646-378-2946
jsteier@troutgroup.com
Adverum Biotechnologies (NASDAQ:ADVM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adverum Biotechnologies (NASDAQ:ADVM)
Historical Stock Chart
From Apr 2023 to Apr 2024